207987-59-5

RS-601 (1-10 mg/kg) clearly inhibits the bronchoconstriction induced by intravenous administration of U-46619 and LTD4 in a dose-dependent fashion in guinea pigs. RS-1452 (10 mg/kg) significantly inhibits U-46619-induced bronchoconstriction, respectively. RS-601 significantly inhibits the late-phase response and LPS-induced AHR at a dose of 10 mg/kg, but does not affect biphasic bronchial responses. RS-601 (3 and 10 mg/kg) also clearly inhibits the AHR^[1].